View in EDS HTML Full Text PDF Full Text

Guanfacine extended-release for cannabis use disorder: a pilot feasibility trial.

Saved in:
Bibliographic Details
Title: Guanfacine extended-release for cannabis use disorder: a pilot feasibility trial.
Authors: Dakwar, Elias (AUTHOR), Mahony, Amy (AUTHOR), Choi, C. Jean (AUTHOR), Pavlicova, Martina (AUTHOR), Brooks, Daniel (AUTHOR), Mariani, John P. (AUTHOR), Levin, Frances R. (AUTHOR)
Source: American Journal of Drug & Alcohol Abuse. 2020, Vol. 46 Issue 1, p44-48. 5p.
Subjects: Marijuana abuse, Fisher exact test, Temperance, Medication therapy management, Log-rank test
Abstract: Background: Currently, there are no established pharmacotherapies for cannabis use disorders (CUDs). As a long-acting alpha-2-adrenergic receptor agonist, guanfacine extended-release (G-XR) could be useful in the treatment of CUDs by mitigating withdrawal and improving behavioral control.Objectives: To evaluate the feasibility and tolerability of G-XR as a treatment for CUDs.Methods: In an eight-week open-label outpatient pilot trial, we evaluated the safety and tolerability of G-XR in 22 cannabis dependent individuals. Using 2 different titration schedules, G-XR was gradually titrated to a dose of 4 mg or the highest dose tolerated. All participants received standard medication management.Results: Retention at week eight was 41%. Average daily amount of cannabis use (in grams: F1,86 = 8.74, p = .004; in dollars: F1,86 = 16.67, p < .0001) and cannabis using days (F1,86 = 7.67, p = .007) significantly reduced over the course of study participation. There were no significant differences between the titration schedules on emergence of side effects (Fisher exact test, p = .378) or retention (Log-Rank Test X21 = 0.021, p = .886). A total of 3 participants achieved 3 weeks or greater of total abstinence.Conclusions: G-XR is a feasible treatment for CUDs, and should be evaluated further in an efficacy trial. [ABSTRACT FROM AUTHOR]
Copyright of American Journal of Drug & Alcohol Abuse is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 141134263
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Guanfacine extended-release for cannabis use disorder: a pilot feasibility trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Dakwar%2C+Elias%22&quot;&gt;Dakwar, Elias&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mahony%2C+Amy%22&quot;&gt;Mahony, Amy&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Choi%2C+C%2E+Jean%22&quot;&gt;Choi, C. Jean&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Pavlicova%2C+Martina%22&quot;&gt;Pavlicova, Martina&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Brooks%2C+Daniel%22&quot;&gt;Brooks, Daniel&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mariani%2C+John+P%2E%22&quot;&gt;Mariani, John P.&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Levin%2C+Frances+R%2E%22&quot;&gt;Levin, Frances R.&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22American+Journal+of+Drug+%26+Alcohol+Abuse%22&quot;&gt;American Journal of Drug &amp; Alcohol Abuse&lt;/searchLink&gt;. 2020, Vol. 46 Issue 1, p44-48. 5p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Marijuana+abuse%22&quot;&gt;Marijuana abuse&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Fisher+exact+test%22&quot;&gt;Fisher exact test&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Temperance%22&quot;&gt;Temperance&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Medication+therapy+management%22&quot;&gt;Medication therapy management&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Log-rank+test%22&quot;&gt;Log-rank test&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: Currently, there are no established pharmacotherapies for cannabis use disorders (CUDs). As a long-acting alpha-2-adrenergic receptor agonist, guanfacine extended-release (G-XR) could be useful in the treatment of CUDs by mitigating withdrawal and improving behavioral control.Objectives: To evaluate the feasibility and tolerability of G-XR as a treatment for CUDs.Methods: In an eight-week open-label outpatient pilot trial, we evaluated the safety and tolerability of G-XR in 22 cannabis dependent individuals. Using 2 different titration schedules, G-XR was gradually titrated to a dose of 4 mg or the highest dose tolerated. All participants received standard medication management.Results: Retention at week eight was 41%. Average daily amount of cannabis use (in grams: F1,86&#160;=&#160;8.74, p =&#160;.004; in dollars: F1,86&#160;=&#160;16.67, p &lt;&#160;.0001) and cannabis using days (F1,86&#160;=&#160;7.67, p =&#160;.007) significantly reduced over the course of study participation. There were no significant differences between the titration schedules on emergence of side effects (Fisher exact test, p =&#160;.378) or retention (Log-Rank Test X21&#160;=&#160;0.021, p =&#160;.886). A total of 3 participants achieved 3&#160;weeks or greater of total abstinence.Conclusions: G-XR is a feasible treatment for CUDs, and should be evaluated further in an efficacy trial. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of American Journal of Drug &amp; Alcohol Abuse is the property of Taylor &amp; Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=141134263
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/00952990.2019.1620259
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 5
        StartPage: 44
    Subjects:
      – SubjectFull: Marijuana abuse
        Type: general
      – SubjectFull: Fisher exact test
        Type: general
      – SubjectFull: Temperance
        Type: general
      – SubjectFull: Medication therapy management
        Type: general
      – SubjectFull: Log-rank test
        Type: general
    Titles:
      – TitleFull: Guanfacine extended-release for cannabis use disorder: a pilot feasibility trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dakwar, Elias
      – PersonEntity:
          Name:
            NameFull: Mahony, Amy
      – PersonEntity:
          Name:
            NameFull: Choi, C. Jean
      – PersonEntity:
          Name:
            NameFull: Pavlicova, Martina
      – PersonEntity:
          Name:
            NameFull: Brooks, Daniel
      – PersonEntity:
          Name:
            NameFull: Mariani, John P.
      – PersonEntity:
          Name:
            NameFull: Levin, Frances R.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2020
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-print
              Value: 00952990
          Numbering:
            – Type: volume
              Value: 46
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: American Journal of Drug & Alcohol Abuse
              Type: main
ResultId 1